Get started
Author

Mingjin Yan

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial
2016 · Joel E Gallant, Eric S Daar, et al. · The Lancet HIV · 165
Determining the Number of Clusters Using the Weighted Gap Statistic
2007 · Mingjin Yan, Keying Ye · Biometrics · 154
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy
2015 · Anthony Mills, Gordon Crofoot, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 139
Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults
2017 · François Raffi, Chloe Orkin, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 83
Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial
2012 · Leszek Bidzan, Atul R. Mahableshwarkar, et al. · European Neuropsychopharmacology · 72
Methods of Determining the Number of Clusters in a Data Set and a New Clustering Criterion
2005 · Mingjin Yan · VTechWorks (Virginia Tech) · 62
A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults
2016 · Gregory D. Huhn, Pablo Tebas, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 55
Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States
2012 · Anthony J. Rothschild, Atul R. Mahableshwarkar, et al. · European Neuropsychopharmacology · 55
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial
2017 · Frank A. Post, Yazdan Yazdanpanah, et al. · HIV Clinical Trials · 31
PDF
Valproic acid‐induced fetal malformations are reduced by maternal immune stimulation with granulocyte‐macrophage colony‐stimulating factor or interferon‐γ
2006 · Terry C. Hrubec, Mingjin Yan, et al. · The Anatomical Record Part A Discoveries in Molecular Cellular and Evolutionary Biology · 29
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial
2018 · Alan Winston, Frank A Post, et al. · The Lancet HIV · 27
SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001).
2023 · Antoine Hollebecque, Juanita Suzanne Lopez, et al. · Journal of Clinical Oncology · 17
Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibody–drug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V-001, trial in progress).
2022 · Amita Patnaik, Justin A Call, et al. · Journal of Clinical Oncology · 6
Strategic Simplification: The Efficacy and Safety of Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) plus Darunavir (DRV) in Treatment-Experienced HIV-1 Infected Adults (NCT01968551)
2015 · Gregory Huhn, Pablo Tebas, et al. · Open Forum Infectious Diseases · 6
Abstract CT078: Phase 1 study of SGN-EGFRd2 in solid tumors (SGNEGFRd2-001)
2024 · Hirva Mamdani, Joel Randolph Hecht, et al. · Cancer Research · 3
937. Virally Suppressed PLH Switching From Abacavir to Tenofovir Alafenamide Did Not Have Changes in Immune Activation or Inflammation
2018 · Nicholas Funderburg, Grace Mccomsey, et al. · Open Forum Infectious Diseases
Efficacy and Safety of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus (HIV)-Infected, Virologically Suppressed Older Adults: Subgroup Analysis of a Randomized, Double-Blind Switch Study
2016 · Eric S. Daar, Joel Gallant, et al. · Open Forum Infectious Diseases
Efficacy and Safety of Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate in HIV-infected, Virologically Suppressed Black and Non-Blacks Adults Through Week 48: Subgroup Analysis of a Randomized Switch Study
2016 · Edwin Dejesus, Richard Elion, et al. · Open Forum Infectious Diseases
PDF
Gene expression changes in the developing neural tube from valproic acid and maternal immune stimulation treatments
2007 · Terry C Hrubec, Wen Li, et al. · The FASEB Journal
Works count: 19
Citation count: 904
H-index: 12
I10-index: 12
Year
Topic
Type